McKesson — Fiscal 2027 Second Quarter Earnings Summary

McKesson Corporation reported fiscal 2027 second-quarter consolidated revenues of $111.0 billion, an 8% increase year-over-year, driven by growth in prescription volumes and specialty product distribution. The company posted adjusted earnings per diluted share of $11.68, representing an 18% increase, and generated $2.9 billion in free cash flow during the quarter. McKesson raised its full-year adjusted earnings per diluted share guidance to a range of $45.60 to $46.40, reflecting strong operational performance across its North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions segments. Strategic developments during the period included the extension of a pharmaceutical distribution partnership with CVS Health, the acquisition of Precision Medicine Group, and a definitive agreement to invest in Option Care Health.